Pituitary Pars Intermedia Dysfunction is one of the most common diseases of the endocrine system that can affect horses.1 PPID causes the horse's pituitary gland, which utilizes hormones to control body functions, to work overtime. This can lead to a variety of problems for horses, ranging from unexplained laminitis to abnormal fat deposits. PPID affects both male and female horses, all breeds and horses as young as 5 years of age.2,3
Why treat with PRASCEND?
FDA-approved as safe and effective4
PRASCEND controls the clinical signs of PPID, which cause pain and discomfort and is the only FDA-approved treatment available to manage PPID in horses. FDA-approval demonstrates the product has met the safety and efficacy requirements to obtain an FDA approval. Decreased appetite was the most common adverse reaction reported in the study.
PRASCEND is indicated to control signs associated with PPID. By controlling these clinical signs, horse owners avoid some of the potential expenses that might be incurred as a result of untreated PPID. Problems may develop as untreated PPID progresses, such as dental disease, chronic infections, recurring or chronic laminitis, or shaggy hair coats that require management, are potentially expensive to treat—not to mention uncomfortable for the horse.
Conveniently packaged, single scored PRASCEND tablets have a validated shelf life and remain at a consistent, effective strength through their noted expiration dates. And the tablets are easy for your horse owners to administer. PRASCEND delivers the reassurance of FDA approval and consistency in dosing. For a small investment per day, your clients can get their horses back to their old selves again by giving a proven safe, stable, and effective tablet that’s easy to include in their normal feeding routine. PRASCEND tablets should not be crushed due to the potential for increased human exposure.
Treatment with PRASCEND improves the quality of life of PPID-affected horses by reducing common signs and decreasing the risk of other illnesses that may be associated with PPID.
PRASCEND has not been evaluated in breeding, pregnant, or lactating animals. As PRASCEND is a dopamine agonist, it may interfere with reproductive hormones involved in these groups of animals.
Horses with PPID will also benefit from an overall excellent general health care along with individual nutrition recommendations from your veterinarian.
Regular care from hoof to teeth
Body clipping, if needed
Following recommendations from your veterinarian
Properly vaccinate your horse
According to recommendations from your veterinarian
Diet and exercise
Ask your veterinarian about the best way to transition your horse to PRASCEND.
Depending on the specific clinical sign, improvement may be observed beginning
within 30 days and continue through 6 months of initial treatment.6
Obtaining FDA approval is a strict and rigorous process. PRASCEND is
manufactured according to the strict specifications set forth by the US Food & Drug
Administration. PRASCEND is manufactured to provide a consistent, safe, and efficacious
PRASCEND is available only through licensed veterinarians. Your veterinarian will calculate the correct dosage based on the needs of your horse and provide you with all dosing and administration information.
PRASCEND tablets can be hidden in an apple or treat. The tablet may be administered orally by dissolving in a small amount of water, with or without sweetener. Administer the liquid with a syringe or as a top-dressing on feed. After dissolving, the tablet should be given immediately. Do not crush the tablet. See complete prescribing information and important safety information in product label.
PRASCEND comes in convenient packaging:
Important Safety Information
FDA Licensing Field Trial Proves PRASCEND® (pergolide tablets) Efficacy4,5
In a large, multi-site field efficacy study, PRASCEND was effective in controlling clinical signs associated with PPID in horses and ponies.
One hundred thirteen male and female horses and ponies representing 16 different breeds in 10 locations throughout the US were evaluated. The horses were either privately or university-owned. Horses were aged 10 to 35 years and weighed 302 lb to 1,370 lb. All horses had been diagnosed with PPID prior to starting treatment with PRASCEND.
All horses received pergolide once daily for 180 days. Because of the progressive, life-threatening nature of unmanaged PPID, an untreated control group was not included in this study. Each horse (baseline clinical signs and endocrine test results) was used as it's own control.
Horses were given PRASCEND tablets containing 1.0 mg of pergolide, as pergolide mesylate. The target
starting dosage for each animal was 2mcg of PRASCEND per kg of body weight. If endocrine
test results remained abnormal at study Day 90, the target dosage was increased to
For complete PRASCEND dosage and administration information, click here
Efficacy study results4,5
Seventy-six percent (86 of 113 horses) were treatment successes based on endocrinologic testing results and/or clinical scores. As seen in Table 1, horses showed improvement in clinical signs within 3 months and further benefits of treatment after 6 months. Hirsutism, the shaggy hair coat considered to be a key indicator of PPID, improved in an impressive 89% of treated horses.
Each of the treatment successes (n=86) showed the following results within 180 days:
FDA licensing field trials have proven PRASCEND safety
To obtain FDA approval a six month margin of safety study was conducted that demonstrated PRASCEND was safe for use in horses at the labeled dose by performing studies that use 2 times the maximum dosage.4,5 In this study, PRASCEND tablets were given once daily at up to 2 times the normal maximum dosage. Thirty-two Paint and Appaloosa horses ranging from 3 to 10 years of age were included in the study.
For added confidence in prescribing PRASCEND, additional safety monitoring of adverse events was conducted throughout the large-scale, multi-site efficacy study.
A total of 122 horses were enrolled in the field study safety analysis. Study horses included both males and females representing 16 different breeds that were either privately or university-owned located at 10 sites throughout the US.
Adverse events associated with PRASCEND included are summarized in the table below. Most of the reactions were either transient or resolved with a temporary dose adjustment.
PRASCEND® (pergolide tablets) Offers Great Value
Because PPID is not a curable disease, daily lifelong therapy is needed to treat the clinical signs of PPID and minimize the secondary complications often associated with the disease. The good news for your clients is, there is a solution that will help manage the disease.
PRASCEND is for use in horses only. Treatment with PRASCEND may cause loss of appetite. Most cases are mild. Weight loss, lack of energy, and behavioral changes also may be observed. If severe, a temporary dose reduction may be necessary. PRASCEND has not been evaluated in breeding, pregnant, or lactating horses and may interfere with reproductive hormones in these horses. PRASCEND Tablets should not be crushed due to the potential for increased human exposure.
1. McGowan TW, Hodgson DR, McGowan CM. The prevalence of equine Cushing's syndrome in aged horses. In: Proceedings from the 25th American College of Veterinary Internal Medicine Forum; June 6-9, 2007; Seattle, WA. Abstract 603.
2. Donaldson MT, McDonnell SM, Schanbacher BJ, Lamb SV, McFarlane D, Beech J. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J Vet Intern Med. 2005;19(2):217-222.
3. Grubbs ST, Neal DL and TJ Keefe. Clinical signs associated with PPID status in a large population of horses. J Vet Intern Med 2015;29:1242
4. PRASCEND (pergolide tablets) [package insert]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2016.
5. PRASCEND (pergolide tablets) [Freedom of Information Summary]. St Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2016.
6. Equine Endocrinology Group PPID Recommendations, 2013